Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 5/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.35 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12898607 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL15003220 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL12669339 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL15003149 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL9008143 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL15304386 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL463607 | 1.00 | TNF (0.46) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL16254154 | 0.98 | TNF (0.47) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL27099540 | 0.98 | TNF (0.47) | TNFMAPK1GJB2SSTR1SSTR2 | |
| SCHEMBL10648977 | 0.95 | TNF (0.51) | TNFMAPK1GJB2SSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170051003-A1 | REAGENT-CONTROLLED STEREOSELECTIVE GLYCOSYLATION | NATIONAL SCIENCE FOUNDATION | 2017-02-23 | — | — | US | disclosed |
| US-9403862-B2 | Reagent controlled stereoselective glycosylation | TRUSTEES OF TUFTS COLLEGE (US) | 2016-08-02 | — | — | US | disclosed |
| US-9359394-B2 | Stereoselective glycosylation reactions | TRUSTEES OF TUFTS COLLEGE (US) | 2016-06-07 | — | — | US | disclosed |
| EP-2411528-B1 | ALPHA-SELECTIVE SIALYL PHOSPHATE DONORS FOR PREPARATION OF SIALOSIDES AND SIALOSIDE ARRAYS FOR INFLUENZA VIRUS DETECTION | ACADEMIA SINICA (TW) | 2015-09-02 | — | — | EP | disclosed |
| US-20150038689-A1 | Reagent-Controlled Stereoselective Glycosylation | NATIONAL SCIENCE FOUNDATION | 2015-02-05 | — | — | US | disclosed |
| US-20140303359-A1 | Stereoselective Glycosylation Reactions | TRUSTEES OF TUFTS COLLEGE (US) | 2014-10-09 | — | — | US | disclosed |
| US-8536153-B2 | Chemical synthesis of phosphatidylinositol mannoside glycans from Mycobacterium tuberculosis | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8524873-B2 | Sugar donor | RIKEN (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8507660-B2 | Alpha-selective sialyl phosphate donors for preparation of sialosides and sialoside arrays for influenza virus detection | ACADEMIA SINICA (TW) | 2013-08-13 | — | — | US | disclosed |
| US-8445652-B2 | 3, 6-O-bridged pyranose inversion compound and process for producing B-O-pyranoside | KWANSEI GAKUIN EDUCATIONAL FOUNDATION (JP) | 2013-05-21 | — | — | US | disclosed |
| US-20070208171-A1 | SUGAR DONOR | RIKEN (JP) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303359-A1 | Stereoselective Glycosylation Reactions | UGGT1, ST6GAL1, FUT6 | TNF 4193/4885MAPK1 2285/4885GJB2 3056/4885 |
| US-20150038689-A1 | Reagent-Controlled Stereoselective Glycosylation | ST6GAL1, UGGT1, GALE | TNF 2604/4885MAPK1 3284/4885GJB2 3502/4885 |
| US-20170051003-A1 | REAGENT-CONTROLLED STEREOSELECTIVE GLYCOSYLATION | ST6GAL1, UGGT1, GALE | TNF 2604/4885MAPK1 3284/4885GJB2 3502/4885 |
| US-20070208171-A1 | SUGAR DONOR | GCK, G6PD, SLC2A4 | TNF 4632/4885MAPK1 633/4885GJB2 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.